Home/ Stocks/ XLO

Xilio Therapeutics, Inc. Common Stock

XLO XNAS

$8.37 +0.51 (+6.49%) ▲ 15-min delayed

Open

$7.80

High

$8.64

Low

$7.80

Volume

73.2K

Market Cap

$41.24M

About Xilio Therapeutics, Inc. Common Stock

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 73 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$19.07M	$-16,287,000	$-0.11
Q2 2025	$8.08M	$-15,844,000	$-0.16
Q1 2025	$2.93M	$-13,265,000	$-0.18
FY 2024	$6.34M	$-58,241,000	$-1.09

Related Market News

No specific coverage for XLO yet. Check out our latest market news or earnings calendar.

Get XLO Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Xilio Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.